

Review Article

Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases

Luiza C. Reis ,¹ Eduardo Milton Ramos-Sanchez ,^{1,2} Fernanda N. Araujo ,¹ Ariane F. Leal,¹ Christiane Y. Ozaki ,¹ Orlando R. Sevillano ,¹ Bernardina A. Uscata ,¹ and Hiro Goto ,^{1,3}

¹Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina, Universidade de São Paulo (IMTSP-USP), São Paulo, Brazil

²Departamento de Salud Pública, Facultad de Ciencias de La Salud, Universidad Nacional Toribio Rodriguez de Mendoza de Amazonas, Chachapoyas, Peru

³Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Correspondence should be addressed to Hiro Goto; hgoto@usp.br

Luiza C. Reis and Eduardo Milton Ramos-Sanchez contributed equally to this work.

Received 24 December 2020; Revised 3 April 2021; Accepted 11 April 2021; Published 5 May 2021

Academic Editor: Gabriela Santos-Gomes

Copyright © 2021 Luiza C. Reis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Leishmaniases are diseases caused by several *Leishmania* species, and many factors contribute to the development of the infection. Because the adaptive immune response does not fully explain the outcome of *Leishmania* infection and considering that the initial events are crucial in the establishment of the infection, we investigated one of the growth factors, the insulin-like growth factor-I (IGF-I), found in circulation and produced by different cells including macrophages and present in the skin where the parasite is inoculated. Here, we review the role of IGF-I in leishmaniasis experimental models and human patients. IGF-I induces the growth of different *Leishmania* species in vitro and alters the disease outcome increasing the parasite load and lesion size, especially in *L. major*- and *L. amazonensis*-infected mouse leishmaniasis. IGF-I affects the parasite interacting with the IGF-I receptor present on *Leishmania*. During *Leishmania*-macrophage interaction, IGF-I acts on the arginine metabolic pathway, resulting in polyamine production both in macrophages and *Leishmania*. IGF-I and cytokines interact with reciprocal influences on their expression. IL-4 is a hallmark of susceptibility to *L. major* in murine leishmaniasis, but we observed that IGF-I operates astoundingly as an effector element of the IL-4. Approaching human leishmaniasis, patients with mucosal, disseminated, and visceral diseases presented surprisingly low IGF-I serum levels, suggesting diverse effects than parasite growth. We observed that low IGF-I levels might contribute to the inflammatory response persistence and delayed lesion healing in human cutaneous leishmaniasis and the anemia development in visceral leishmaniasis. We must highlight the complexity of infection revealed depending on the *Leishmania* species and the parasite's developmental stages. Because IGF-I exerts pleiotropic effects on the biology of interaction and disease pathogenesis, IGF-I turns up as an attractive tool to explore biological and pathogenic processes underlying infection development. IGF-I pleiotropic effects open further the possibility of approaching IGF-I as a therapeutic target.

1. Introduction

Leishmaniases are considered neglected tropical diseases caused by parasites of the order Kinetoplastida, family Trypanosomatidae, and genus *Leishmania*, affecting one million people globally each year and endemic in 98 countries. The

transmission occurs through a sandfly bite that inoculates promastigotes into the skin, which transform into amastigotes and proliferate within phagocytic mononuclear cells. The infection can be asymptomatic or symptomatic, leading to a wide spectrum of clinical manifestations ranging from localized, disseminated, or diffuse cutaneous lesions or

mucosal lesions to viscera involvement such as the liver and spleen [1]. The establishment of these different clinical forms depends on the parasite's species and on the vector, in addition to the epidemiological characteristics and genetic and immunological constitution of the host [2], where both innate and adaptive immune responses can drive the development or control of infection.

The beginning of our studies on insulin-like growth factors on *Leishmania* and leishmaniasis backs to the nineties when the main focus on leishmaniasis research was the cell-mediated immune response. At the end of the eighties, T helper 1 (Th1) was related to resistance and T helper 2 (Th2) to susceptibility to *Leishmania major* infection in studies using inbred mouse strains. The susceptibility was attributed to early Th2 cell activation present in BALB/c mice and the resistance to Th1 cells in C57BL/6 mice by the infection. Subsequent studies using different approaches as cytokine neutralization, specific cell response induction, or inhibition of the immune system's elements through molecular deletions confirmed this view, but others pointed flaws in this model. Similar studies using other *Leishmania* species also showed that the adaptive immune response does not explain the infection's resistance and susceptibility profiles. Further, human leishmaniases' pathogenesis cannot be explained only based on resistance and susceptibility to parasite growth.

In this review, we initially present some data related to the involvement of adaptive immune response on *Leishmania major* and *Leishmania donovani/Leishmania infantum* infections that do not fully clarify infection development to justify the focus here on nonspecific factors. Then, we present data including studies on the innate immune response that points out our research on the IGF-I growth factor as an element that may contribute to *Leishmania* infection.

2. Adaptive Immune Response in Leishmaniases: Flaws

2.1. *Leishmania major*. The experimental model using *L. (L.) major* has been used to characterize the immune response on resistance or susceptibility to infection related to the Th1 and Th2 cell activation, respectively [3]. The role of cytokines in the Th1 and Th2 paradigm has been questioned by results suggesting that the resistance and susceptibility regulation are much more complex, involving cytokine production and other factors [4–9]. Studies have demonstrated that the interferon- (IFN-) γ and interleukin- (IL-) 4 production are similar in susceptible and resistant mice in the early stage of infection [3, 10, 11]. Further, IL-4 production in resistant mice does not alter the evolution towards progressive disease, similarly seen in C3H mice treated with IL-4 or anti-IL-12 at the beginning of infection. These mice presented a solid but transient increase in the IL-4 level, with no change in their resistant phenotype [12–14]. Another study showed that the transfer of BALB/c T cells with high IL-4 expression to genetically resistant chimeric mice having a C57BL/6 background did not result in susceptibility [15]. These questions on the Th1 and Th2 paradigm in leishmaniasis also become evident in infections caused by other *Leishmania* species.

2.2. *Leishmania donovani/Leishmania infantum*. In contrast to the *L. major*-infected mouse model's immune response very much scrutinized, the immune mechanisms in experimental visceral leishmaniasis (VL) are less explored. Resistance in VL involves CD4 $^{+}$ and CD8 $^{+}$ T cells, IL-2, IFN- γ , and IL-12, the latter in an IFN- γ -independent mechanism and linked to transforming growth factor β (TGF- β) production. Susceptibility involves IL-10 but not IL-4 and B cells [16]. Studies on *L. donovani* and *L. infantum* infections in mice and humans [17–20] suggest that control of infection was independent of the Th1 and Th2 cytokine differential production (IFN- γ /IL-4 balance) [20]. The resistance to *L. donovani* and induction of granuloma formation are dependent on the generation of an IFN- γ response by both CD4 $^{+}$ and CD8 $^{+}$ T cells. IFN- γ activates macrophages to produce antimicrobial reactive nitrogen and oxygen intermediates [21], also important in driving granuloma maturation. Most *L. donovani*-infected mouse strains control infection spontaneously, becoming immune for subsequent infections. In these immune animals, upon reinfection, the elements involved in resistance are different, i.e., CD8 $^{+}$ T cells and IL-2 [16]. These experimental VL findings do not contribute substantially to understand active human VL where the disease is progressive and lethal if not treated.

In active human VL, the patients present fever, hepatosplenomegaly, hypergammaglobulinemia, pancytopenia, and significant weight loss [1]. Most of the studies focus on the suppression of the T cell responses [22]. Immunosuppression is characterized as *Leishmania* antigen-specific, where T cells, Th2 cells, and adherent antigen-presenting cells are involved [16]. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are negative regulators of T cells and are expressed on exhausted or anergic T cells in active infection, taking part in immunosuppression. The evoked mechanism is the induction of an increased level of TGF- β and apoptosis of CD4 $^{+}$ T cells and inhibition of macrophage apoptosis by *Leishmania* infection [23]. T cell apoptosis, mainly CD4 $^{+}$ T cells, accompanied by a significant decrease in IL-2 and IFN- γ secretion and unaltered IL-4 secretion, was observed during *L. donovani* infection and was also related to immunosuppression [16]. Other immunosuppressive mechanisms established during VL may be mediated through regulatory T cells, secreting regulatory cytokines like IL-10 and TGF- β and expressing inhibitory molecules such as CTLA-4 and IL-35 [23].

In contrast to the studies on immunosuppression, other data suggest intense immune activation in active VL [24]. Studies on peripheral blood mononuclear cells raised data that suggest immunosuppression. However, findings in lymphoid organ samples such as bone marrow and spleen show high expression of tumor necrosis factor α (TNF- α) and IFN- γ mRNA levels and high IFN- γ serum level as a consequence [25, 26]. A study showing exhaustion of the immune system [27] reinforces this view. All these studies focusing on the balance between elements of adaptive immune mechanisms are aimed at explaining the active disease's development. Still, no clear answer was achieved, demanding the investigation on other components as the nonspecific factors.

3. Growth Factors in the Innate Response in Leishmanias

As the adaptive immune response does not fully explain the control or development of *Leishmania* infection and the initial events that occur immediately after the vector's promastigote inoculation are crucial, we chose to investigate growth factors present on the inoculation site. Once inoculated into the skin, the parasites immediately encounter innate immune elements, including growth factors such as TGF- β and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The role of TGF- β as an important immune regulator in leishmaniasis has been demonstrated *in vitro* [28–31] and *in vivo* [32–34]. TGF- β can inhibit macrophage activation through the blockage of nitric oxide (NO) production, leading to an increase in the parasitic load. Further, a synergistic effect between TGF- β and EBI-3 (Epstein Barr virus-induced gene 3 or IL-27 β) on suppression of BALB/c mouse immune response infected by *L. donovani* was observed [35]. Interestingly, TGF- β homolog found in *Lutzomyia longipalpis* was suggested to contribute to the *L. infantum* survival within the vector [36].

In addition to TGF- β , GM-CSF can interact with *L. amazonensis* promastigotes, promoting their growth and protecting them from death by thermal shock [37, 38]. In accordance, the rGM-CSF (recombinant GM-CSF) treatment in *L. major*-infected BALB/c mice promoted an enlargement in lesions and increased parasite load, as well as *L. major*-infected macrophages incubated with rGM-CSF presented an increased parasite load [39]. Further, the GM-CSF was used topically during Miltefosine treatment in American tegumentary leishmaniasis without success [40, 41]. In a multiomic study in cutaneous leishmaniasis patients, diminished concentrations of GM-CSF, IFN- α 2, IL-6, and IL-3 and increased eotaxin levels were related to treatment failure [42]. However, other studies show opposite results; parasites are eliminated in *L. tropica*-, *L. mexicana*-, and *L. donovani*-infected macrophages upon activation with GM-CSF [43–45]. Moreover, mice with a null mutation in the gene for the beta common (β c) chain of the receptors for GM-CSF, IL-3, and IL-5 infected with *L. major* presented resistance to infection [46].

In this context, we have started studying another growth factor, the insulin-like growth factor-I (IGF-I). Its role in *Leishmania* infection was considered because it is produced by different cell types, including macrophages that harbor the parasites. Also, it is present in the skin, where the parasite initiates the infection [47].

The IGF-I is a hormone that presents a molecular structure relatively similar to insulin, being produced primarily by the liver under the control of growth hormone (GH). As a polypeptide phylogenetically well preserved, the IGF-I presents a molecular mass of approximately 7.5 kDa. It is present in the circulation bound to a complex of carrier proteins called insulin-like growth factor-binding proteins (IGFBPs). Since its affinity for IGFBPs is greater than for its receptor, in the extracellular environment, most IGFs bind to IGFBP, of which IGFBP-3 is the most abundant in human serum

[48]. As mentioned before, different cell types produce IGF-I, including macrophages that produce and harbor the IGF-I with 26 kDa that will be cleaved in a 7.5 kDa molecule to be secreted. IGF-I exhibits pleiotropic properties, including the ability to promote cellular proliferation, differentiation, nutrient transport, energy storage, gene transcription, protein synthesis, modulation of the immune response and inflammation, and epigenetic modifications [47, 49, 50]. Of note, IGF-I can trigger and/or modulate more than 200 genes depending on cell types, tissues, development stages, among others [51, 52]. In addition to insulin, the IGF-II is another molecule that presents considerable similarity with IGF-I, and its effect was observed on the stimulation of *Giardia lamblia* trophozoite growth [53]. Despite the substantial similarity between IGF-I and IGF-II, only IGF-I presented effect on *Leishmania* infection and proliferation [54–56]. The same was observed on the development of infection caused by other pathogens, like *Mycobacterium leprae*, *Schistosoma mansoni*, and *Schistosoma japonicum* [57, 58].

The IGF-I exerts its biological effects binding to its receptor (IGF-IR), which is present in several cell types, mainly in macrophages, activating the intracellular signaling cascade. The phosphoinositide-3 kinase/protein kinase-B (PI3K/AKT) and the mitogen-activated protein kinase (Ras/MAPK/ERK) are two main pathways activated by IGF-I. Their stimulation may also occur by binding to the insulin receptor (IR) when its free form is present in excess. Since IGF-IR and IR are highly homologous tyrosine kinase receptors sharing many signaling pathway components and inducing insulin receptor substrates 1 and 2 (IRS1/2) in addition to AKT and MAPK phosphorylation [59–61], the IGF-I binding to IR can result in a signaling cascade comparable to the one triggered by the IGF-IR, generating similar effects.

It has been demonstrated that some physiological processes are controlled by the immune and endocrine systems reciprocally, through cytokine and hormone-regulated actions [62–64]. Regarding IGF-I, some factors such as cytokines can regulate its expression in macrophages. Macrophage stimulation, *in vitro*, by IFN- γ results in a decrease and by IL-4 and IL-13 in an increase of IGF-I expression [65–67]. On the other hand, IGF-I can also regulate cytokine production. Phytohemagglutinin- (PHA-) stimulated human peripheral blood mononuclear cells (PBMC) in the IGF-I presence showed an increase in IL-10 and IL-4 and decrease in IFN- γ secretion. In accordance, the IL-10 mRNA level increased, as well as IL-10 secretion in PBMC-derived T cells under the same conditions [68]. Further data showing expression of IGF-I receptor expression upon T cell activation or modulation of adaptive immune elements by IGF-I [69–72] suggest an important role of IGF-I in immunity.

This review will present the IGF-I as an active participant both in experimental infection by *Leishmania* spp and human leishmaniasis.

4. IGF-I in Experimental Leishmaniasis

4.1. Effect of IGF-I on *Leishmania* Promastigotes and Amastigotes.

The IGF-I likely interacts with *Leishmania*




FIGURE 1: Growth curves of *Leishmania* spp promastigotes upon IGF-I stimulus. *L. major*, *L. amazonensis*, *L. infantum*, and *L. braziliensis* promastigotes (5×10^5 /mL) were cultured in 199 medium (Cultilab, Brazil) and Schneider's Insect medium (Sigma-Aldrich, USA), respectively, supplemented with 5% heat-inactivated fetal calf serum (FCS) (Cultilab, Brazil) at 26°C, with or without 50 ng/mL IGF-I (rIGF-I, R&D Systems, USA). The growth of parasites was monitored by daily counting, for 10 days, in a Neubauer chamber, and the results are presented as the number of parasites $\times 10^7$ /mL (mean \pm standard deviation) from three independent cultures with or without 50 ng/mL IGF-I. * $p < 0.05$ (one-way ANOVA) compared with the culture without IGF-I (adapted from Reis et al. [65]).

immediately after its inoculation into the host's skin and after being phagocytized by macrophages. For years, we studied the participation of this growth factor directly on *Leishmania* spp promastigotes and amastigotes in experimental in vitro and in vivo infection and human infection.

We initially evaluated the IGF-I effect on promastigotes and axenic amastigotes of different *Leishmania* species by adding extrinsic IGF-I (i.e., recombinant human IGF-I) in physiological concentrations [54–56]. Analyzing the IGF-I effect throughout the promastigote growth curves of each species, we observed increased proliferation of the parasites in the presence of IGF-I. Its effect was more evident when they reached the stationary growth phase (Figure 1). Thus, the promastigotes' response to extrinsic IGF-I suggests that their contact with the host's IGF-I when inoculated into the skin can substantially affect them at the initial stage of infection.

Subsequently, binding of IGF-I was shown to induce phosphorylation of tyrosine (185 kDa and 60 to 40 kDa proteins) and serine-threonine residues (110 kDa and 120 and 95 kDa proteins) in promastigotes and axenic amastigotes,

in a stage-specific effect [73]. When analyzing the interaction between IGF-I and parasites, it was shown that IGF-I binds specifically to a single-site putative receptor at the parasite membrane. The receptor is a monomeric glycoprotein with a molecular mass of 65 kDa and is antigenically related to the α chain of human type 1 IGF-I receptor [74]. This specific IGF-I receptor found on the surface of *Leishmania* promastigotes and amastigotes differs considerably from those found on mammalian cells. In human cells, the IGF-I receptor is constituted by two alpha and two beta chains with a molecular mass of 135 and 93 kDa, respectively [74, 75]. Upon IGF-I stimulation, the receptor goes through autophosphorylation on tyrosine residues, activating the signaling pathway. Activation of the IGF-I receptor on *Leishmania* also leads to the phosphorylation of a 185 kDa molecule that is homologous to the insulin receptor substrate present in human cells, the IRS-1. IRS-1 is a critical adapter protein involved in IGF-I signaling and is considered a docking protein, playing a central role in the intracellular signaling network [74, 76]. We may speculate that the receptor functions as part of an array of adaptive responses developed by the parasite to survive




FIGURE 2: Scheme of the effect of extrinsic IGF-I (rIGF-I) in the L-arginine metabolic pathway activation in macrophages infected by *L. amazonensis* and *L. major*. In RAW 264.7 cells or BALB/c mouse peritoneal macrophages infected with *L. amazonensis* or *L. major* promastigotes and stimulated with 50 ng/mL recombinant IGF-I (rIGF-I, R&D Systems, USA), the parasitism, arginase mRNA expression, and arginase activity, nitric oxide synthase 2 (NOS2) mRNA expression, and nitric oxide production (Griess reaction) were evaluated. Extrinsic IGF-I induced an increase in arginase expression and arginase activity in both parasites and macrophages, decreased the production of NO, and increased the parasitism in *L. amazonensis*- and *L. major*-infected cells, comparably.

within the host. Thus, it may be considered a possible vaccine target. In fact, it has been approached in schistosomiasis since the IR in *Schistosoma mansoni* and *S. japonicum* were discovered. These worms like *Leishmania* use the host's hormones and nutrients for their development. Their insulin receptors have been studied as a vaccine target in animal models to prevent transmission [57].

4.2. Effect of IGF-I on Leishmania-Macrophage Interaction. Moving to *in vivo* studies using a cutaneous leishmaniasis model in BALB/c mice, we have shown that the preincubation of *L. amazonensis* promastigotes with IGF-I promotes a significant increase in the footpad lesion size, 21 days post-infection. We observed an increase in the number of parasites in the lesion accompanied by an inflammatory infiltrate. These results suggest that IGF-I has a significant role in the innate immune response during the infection, favoring the parasite growth within macrophages [77].

Since IGF-I favors the macrophage's parasite growth, this growth factor probably affects the macrophage's metabolic machinery. The macrophages are key cells in the establishment of *Leishmania* infection. Depending on the cells' activation stimuli, *Leishmania* infection's development will result in progression or cure. One of the mechanisms involved in these processes is the L-arginine metabolic pathway. The L-arginine enters the cells from the extracellular milieu by the cationic amino acid transporter 2 (CAT-2B), a member of the classical amino acid cationic transporter system y⁺ (SLC7) [78]. When this amino acid is oxidized by the nitric oxide synthase 2 (NOS2), it generates nitric oxide (NO), one of the main leishmanicidal elements. However, when the enzyme arginase hydrolyzes L-arginine, polyamines are generated, promoting *Leishmania* proliferation [79–81]. Thus, we addressed the study of extrinsic IGF-I's effect on the parasite-macrophage interaction *in vitro*, evaluating the

L-arginine metabolic pathway in macrophages' infection with *L. amazonensis*.

In this approach, we observed that IGF-I favored parasite growth in *L. amazonensis*-infected macrophages. It occurred through an increase in arginase mRNA expression and arginase activity in both parasites and macrophages and decreased the production of NO by macrophages [55]. As each species of *Leishmania* behaves differently, we analyzed the role of extrinsic IGF-I on *L. major*. Similarly to those results obtained with *L. amazonensis*, in *L. major*-infected macrophages, IGF-I favored the parasite proliferation within the macrophage inducing the arginase activation with an increase of arginase mRNA expression and arginase activity in both parasites and macrophages and a decrease in the NOS2 mRNA expression and the production of NO by macrophages [65, 82] (Figure 2). These results showed the effect of extrinsic IGF-I on L-arginine metabolism leading to the parasite's proliferation within the macrophage.

It is worth mentioning that in *Leishmania* infection, the fate of host-parasite interaction depends on the *Leishmania* species involved. With this in mind, we evaluated the effect of IGF-I on the macrophage infection with other species, *L. infantum*, which causes visceral leishmaniasis (VL) and *L. braziliensis*, which is responsible for the cutaneous (CL), disseminated (DL), and mucosal (ML) forms of the disease.

For the evaluation of the IGF-I effect on *L. infantum* infection, we used the THP-1 human monocytic cell line and murine macrophages. In *L. infantum*-infected THP-1 cells upon IGF-I stimulus, the increase in parasitism was not evident, only a slight tendency, accompanied by an increase in NO production and no difference in arginase activity (Figures 3(a)–3(c)). We observed similar results in *L. infantum*-infected bone marrow-derived murine macrophages enquiring whether the cell type influences these results. We noted an increasing trend in parasitism, accompanied by




FIGURE 3: Parasitism and nitric oxide production in *L. infantum*-infected cells upon extrinsic IGF-I stimulus. THP-1 cells (a–c) or BALB/c mouse bone marrow-derived macrophages (d–f) were infected with *L. infantum* promastigotes and stimulated with recombinant IGF-I (rIGF-I, 50 ng/mL; R&D Systems, USA) for 24 and 48 hours. One representative experiment from three independent assays is shown. THP-1 cells were differentiated into macrophages with 20 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, USA) for 24 hours. Then, the cells were washed and allowed to rest in a fresh medium for 48 hours before infection with *L. infantum* promastigotes. The parasitism (median number of parasites per 100 cells), nitric oxide production (Griess Reagent), and arginase activity (urea production) were determined after 24 and 48 hours of incubation.

increased NO production upon stimulation with IGF-I and no difference in arginase activity (Figures 3(d)–3(f)). Thus, unlike *L. major* and *L. amazonensis* infection, these data suggest that IGF-I does not significantly influence *L. infantum* amastigote proliferation. It may be related to the difference in the L-arginine metabolic pathway in this *Leishmania* species, where arginase does not seem essential for polyamine production. In studies with *L. donovani*, a related species that cause VL, arginase-deleted amastigotes survive within the cell without polyamine supplement but not promastigotes [83–85].

Further, in *L. infantum*-infected BALB/c and Swiss Webster mice, in the presence of spleen and liver cells producing high NO levels but with low arginase activity, the parasites continue multiplying within the host cells [86]. In vitro, *L. infantum* survives in the presence of high amounts of NO added in the culture medium [87]. Altogether, these data support the view that viscerotropic strains show differences in L-arginine metabolism.

As observed with other *Leishmania* species, the extrinsic IGF-I promoted *L. braziliensis* promastigote proliferation (Figure 1). However, this effect was not evident in *L. braziliensis* amastigotes within THP-1 cells upon stimulation with IGF-I. Analyzing the parasitism upon IGF-I stimulus in THP-1 cells infected with parasites isolated from patients

presenting different clinical manifestations, CL, ML, and DL, no differences were observed. We noted only a slight tendency to increase and decrease parasitism in cells infected with parasites derived from ML and DL patients, respectively. We also investigated the involvement of IGF-I on arginase activation in both *L. braziliensis* promastigote-infected THP-1 cells. In promastigotes isolated from CL and DL patients, the arginase activity was increased after IGF-I stimulation, while in parasites isolated from ML patients, a decrease was observed. It is worth mentioning that the ML-derived parasites presented a higher arginase activity when compared with CL- and DL-derived parasites. Besides the alteration in arginase activity in promastigotes, no difference in arginase activity was detected in macrophages infected with those parasites derived from different disease manifestations [88, 89]. Besides, no differences were observed on NO production between the groups stimulated or not with IGF-I (personal communication). Macrophage metabolism in *L. braziliensis* derived from diverse clinical manifestations is poorly understood, demanding more studies on the role of IGF-I.

4.3. Effect of Macrophage Intrinsic IGF-I on Intracellular *Leishmania* Growth. As macrophages contain endogenous IGF-I in the cytoplasm, we decided to evaluate IGF-I's role




FIGURE 4: Detection of IGF-I within RAW 264.7 macrophages following infection with *Leishmania major* promastigotes. Colocalization of IGF-I and *Leishmania* was analyzed using immunofluorescence. Following a 24 h in vitro infection, cells were fixed in 4% paraformaldehyde (Sigma-Aldrich, USA), washed in 0.01 M phosphate-buffered saline, pH 7.2 (PBS), blocked for one hour with 2% bovine serum albumin (BSA; Sigma-Aldrich, USA) in PBS, and incubated overnight with monoclonal goat anti-mouse IGF-I antibody (1 : 75; R&D Systems, USA) and a polyclonal mouse anti-*Leishmania* antibody (1 : 400) [136]. Anti-goat IgG Alexa Fluor-546 (1 : 200, Invitrogen, USA—shown in red) and anti-mouse IgG Alexa Fluor-488 (1 : 400, Invitrogen, USA—shown in green) were used as secondary antibodies. 4,6-Diamidino-2-phenylindole (DAPI, Invitrogen, USA—shown in blue) was used to stain nuclei. Images were captured using a Leica LSM510 confocal microscope with a 63x objective and oil immersion (adapted from Reis et al. [82]).

produced by the macrophages (intrinsic IGF-I) in *Leishmania* infection. Under confocal microscopy, we showed that the intrinsic IGF-I interacts with intracellular *Leishmania* parasites [82] (Figure 4).

Since the interaction occurs between intrinsic IGF-I and intracellular parasites, we evaluate the parasitism upon inactivation of intrinsic IGF-I. Using a knockdown strategy, the *Igf-I* mRNA was silenced with IGF-I small interfering RNA (siRNA) in *L. major*-infected macrophages. In the siRNA-transfected group, we observed a significant decrease in parasitism, accompanied by decreased arginase mRNA expression and arginase activity in both parasites and macrophages and an increase in the *Nos-2* mRNA expression and NO production, when compared with the control group without siRNA transfection. This effect was reversed by the addition of recombinant IGF-I (rIGF-I), which induced an increase in the number of parasites and increased the levels of *Leishmania* arginase mRNA expression and arginase activity, accompanied by a decrease in the *Nos-2* mRNA expression and NO production [65].

We observed similar results when the IGF-I silencing strategy was employed in *L. amazonensis*-infected macrophages. We observed a significant decrease in parasitism accompanied by an increase in the NO production in the groups treated with siRNA compared with the control without siRNA (Figure 5). In another study, macrophages from growth hormone (GH)/IGF-I-deficient individuals, due to the growth hormone-releasing hormone receptor gene mutation, were assayed in vitro for *L. amazonensis* infection. It was observed that the macrophages isolated from these individuals were less prone to infection than healthy control

macrophages [90]. These data certainly confirmed the role of intrinsic IGF-I in intracellular parasite growth.

5. IGF-I and Cytokines

In *Leishmania* infection, the cytokines produced by macrophages and lymphocytes have an important participation in the interplay between parasite and the host involving IGF-I. In *L. amazonensis*-infected macrophages, the mechanisms leading to parasite growth upon IGF-I stimulus differed depending on the parasite life cycle stage used for infection. When cells were infected by promastigotes, upon IGF-I stimulus, this activation likely occurred through modulation of cytokine production, inducing a decrease in TNF- α and an increase in TGF- β and IFN- γ [55]. In cells infected by amastigotes, the mechanism was diverse. IGF-I induced phosphatidylserine exposure on the parasite surface that likely activated the macrophage arginase [91].

Other cytokines can act on the IGF-I expression like IFN- γ which promotes a reduction in the IGF-I expression, while IL-4 and IL-13 promote an increase in IGF-I expression [65–67]. These data suggest that IGF-I is involved in the development of the adaptive immune response in leishmaniasis.

The idea of immune-endocrine cross-talk has been described in other studies examining the roles of prolactin, GH, IGF-I, and thyroid-stimulating hormone in the development, maintenance, and function of the immune system, which in turn cause changes in the endocrine system [92–94]. The interaction between the endocrine




FIGURE 5: Parasitism in *L. major*- or *L. amazonensis*-infected macrophages upon IGF-I siRNA transfection. RAW 264.7 cells infected with *L. major* or *L. amazonensis* promastigotes transfected with or without 150 μ M IGF-I siRNA for 6 hours. The parasitism (median number of parasites per 100 cells) was evaluated after 24 and 48 hours. One representative experiment from three independent assays is shown. * $p < 0.05$ (ANOVA and Tukey's tests).

and immune systems is somewhat expected, as they share several ligands and receptors in their signaling pathways [65].

Interactions between IGF-I and the immune system are complex, bidirectional, and not fully explained. IGF-I could modulate the inflammatory response and the activity of systemic inflammation [95]. Studies have indicated that chronic inflammation could suppress the IGF-I axis via several mechanisms such as downregulation of IGF-I receptors, disruption in the IGF-I signaling pathways, dysregulation of IGFBPs, reduced IGF bioavailability, and modified gene regulation through the changes in the microRNA expression [95, 96]. Proinflammatory cytokines such as IL-6, TNF- α , and IL-1 β impair the activity of the IGF-I axis by dysregulation of its intracellular mediators, such as mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinases and PI3K [97]. IGF-I can reduce inflammation induced by oxidized low-density lipoprotein treatment by reducing high-mobility group box 1 (HMGB1) release, a potent stimulator of tissue damage and inflammation, after stimulation with pathogens or a factor passively released by necrotic cells, activating nuclear factor kappa B (NF- κ B) [98, 99]. In another study on postmyocardial infarction, IGF-I decreased myocardium cell apoptosis and inhibited gene expression and production of proinflammatory cytokines, such as TNF- α , IL-1 β , and IL-6 [100]. Overall, most of the data appoint the effect of IGF-I on the innate inflammatory response.

In leishmaniasis, the specific immune response is well established in the *L. major*-infected mouse model, where Th1 and Th2 cytokines were, respectively, related to resistance and susceptibility to the infection. When Th1 cells are predominantly activated, the cytokines IL-2, IFN- γ , TNF- β , and IL-12 will be produced. Then, macrophages are activated and NOS2 induced, which metabolizes L-arginine, generating citrulline and NO associated with increased microbicidal activity. However, when Th2 cells are predominantly activated, mainly IL-4, IL-10, TGF- β , and IL-13 will be produced. Again, macrophages are activated alternatively, and arginase I expression and arginase activity are induced, lead-

ing to polyamine production that contributes to parasite proliferation [3].

When we analyzed IGF-I expression and the parasitism of *L. major* infection in vitro, macrophages stimulated with IFN- γ exhibited a reduction in the parasite load, accompanied by a parallel reduction in IGF-I expression and arginase activity and an increase in NO production. Further, IL-4 and IL-13 stimuli increased the parasitism, followed by a parallel increase in IGF-I expression and arginase activity and reduced NO production [65]. These data showing the similar effects of those cytokines on IGF-I expression and parasitism compelled us to explore this hormone's interference on the effects of cytokines during *Leishmania* infection.

As shown above, the Th1 and Th2 paradigm defined in the murine model with *L. major* infection has imperfections, and IL-4 related to susceptibility cannot be considered valid in any situation. Recently, in another *Leishmania* species, IL-4 was considered cytokine determining resistance in a *L. donovani*-infected BALB/c mouse [20]. Since the studies suggest that the susceptibility profile is not exclusively due to IL-4, and analyzing the signaling pathways of IL-4/IL-13 compared with the IGF-I pathway, we noticed shared components, suggesting that IGF-I and IL-4 may reciprocally interfere during *Leishmania* infection [65]. Thus, we proceeded with the study on the interference of IGF-I on IL-4 effect in *L. major*-macrophage interaction.

In *L. major*-infected macrophages stimulated with cytokines upon *Igf-I* mRNA expression silencing, the parasitism did not show the specific cytokine effect's expected result. Increased parasitism would be anticipated with IL-4 and IL-13 stimuli. However, they were utterly ineffective when the *Igf-I* mRNA was silenced. The effects of IL-4 and IL-13 on *Igf-I* mRNA-silenced cells were restored by the addition of rIGF-I in the culture, in a mechanism dependent on *Leishmania* arginase production [65].

Our results showed that IGF-I is necessary for IL-4 to exert its effect on parasite proliferation in macrophages. IGF-I and the cytokines IL-4 and IL-13 share common




FIGURE 6: The effects of IGF-I siRNA and IL-4 on components of the IGF-I signaling pathways: levels of phosphorylated p44 (ERK), p38 (MAPK), and AKT proteins. *L. major* promastigote-infected or noninfected RAW 264.7 cells transfected with or without IGF-I siRNA were stimulated for 30 minutes with IL-4 (2 ng/mL; R&D Systems, EUA) and recombinant IGF-I (50 ng/mL; R&D Systems, EUA). Cells were lysed, the proteins were separated in 10% SDS-PAGE, and subsequently, a Western blotting was performed using anti-phospho-p44 (137F5, Cell Signaling Technology, USA), anti-phospho-p38 (D13E1, Cell Signaling Technology, USA), and anti-phospho-AKT (Ser473, Cell Signaling Technology, USA) antibodies. Protein bands corresponding to protein expression levels were submitted to a densitometric analysis (AlphaEaseFC™ software 3.2 beta version; Alpha Innotech Corporation, USA), and data are expressed in arbitrary units (adapted from Reis et al. [65]).

components in their intracellular signaling pathways. IGF-I triggers MAPK (ERK) and PI3K pathways [59, 101], and IL-4 sequentially activates IRS-2 and the PI3K/Akt and Ras-MAPK pathways [61, 102]. We observed an increase in the levels of these phosphorylated proteins in all groups treated with IL-4. Upon *Igf-I* mRNA silencing, we observed a decrease in the expression of all phosphoproteins, and interestingly, IL-4 stimulation did not completely restore the decreased expression of phospho-p44 (ERK), phospho-p38 (MAPK), and phospho-AKT [65] (Figure 6). We thus considered IGF-I as the effector element for the IL-4 effect in promoting susceptibility in *L. major* infection.

The participation of both Th1 and Th2 cytokines in resistance and susceptibility was defined on *L. major*-infected murine model infection, but it may not work in other *Leishmania* species such as *L. amazonensis*. IFN- γ promotes parasite growth in *L. amazonensis* amastigote-infected macrophages [103]. In our study with *L. amazonensis*-infected macrophages, IFN- γ induced increased parasitism and NO production and decreased IGF-I expression, with no correlation

with the parasitism. The IL-4 and IL-13 stimuli also promoted an increase in parasitism associated with an increase in IGF-I expression and an increase in arginase activity. Silencing *Igf-I* mRNA using IGF-I siRNA, the IL-4 and IL-13 stimuli led to decreased parasitism compared with their controls without siRNA. These data suggested that in the infection by *L. amazonensis*, IGF-I is also needed to promote susceptibility to infection (Figure 7). However, the effect of IFN- γ and interplay with IGF-I on *L. amazonensis* proliferation need further studies.

Thus, the susceptibility and resistance observed in *L. major*- and *L. amazonensis*-infected mouse strains may be due to cytokines to some extent, but the susceptibility essentially depends on the presence of IGF-I.

6. IGF-I in Susceptible and Resistant Leishmaniasis Mouse Models

In light of our findings showing IGF-I ruling susceptibility and resistance to *L. major* infection in vitro, we proceeded




FIGURE 7: Parasitism in response to cytokine treatments and IGF-I siRNA transfection. Parasitism (median number of parasites per 100 cells) in *L. amazonensis*-infected RAW 264.7 cells transfected with or without 150 μ M IGF-I siRNA for 6 hours and then were stimulated with IFN- γ (200 U/mL; R&D Systems, EUA), IL-4 (2 ng/mL; R&D Systems, EUA), or IL-13 (5 ng/mL; R&D Systems, EUA) for 24 (a) and 48 (b) hours. One representative experiment from three independent assays is shown. * $p < 0.05$ (ANOVA and Tukey's tests).

to evaluate the participation of IGF-I in vivo in *L. major*-infected susceptible (BALB/c) and resistant (C57BL/6) mouse strains. In control BALB/c mice, the lesion continuously progressed as expected, while in those animals injected with parasites preincubated with IGF-I, the lesion development was accelerated, becoming larger when compared with the control. In contrast, in control C57BL/6 mice, the lesions progressed for three weeks and then stabilized and tended to diminish, but in those animals infected with parasites preincubated with IGF-I, the lesion interestingly progressed continuously, and it was significantly greater than that in the control, although smaller than that in the BALB/c mouse.

The previous data, showing that the transfer of BALB/c highly expressing IL-4 cells to genetically resistant chimeric mice on a C57BL/6 background did not result in susceptibility [15], suggested that the infection outcome is not governed only by the type of cytokine produced. Then, we asked whether IGF-I expression in mouse strains may explain the *L. major* infection outcome. The IGF-I expression in susceptible BALB/c mice and resistant C57BL/6 mice infected with *L. major* was indeed different. We evaluated the *Igf-I* mRNA by qPCR and IGF-I expression in anti-IGF-I labeled cells under confocal microscopy. By both approaches, IGF-I was detected in higher levels in BALB/c mice-derived peritoneal macrophages than in C57BL/6 mice-derived cells [65], suggesting that background expression of IGF-I may count determining susceptibility to *L. major* infection in mice.

Remarkably, in the *L. braziliensis*-infected mice, the disease development is not tangible, with tiny lesions [104]. The same is observed in a visceral leishmaniasis murine model using *L. donovani* or *L. infantum* that presents self-controlled disease [105, 106]. Coincidentally, the IGF-I in vitro effect on these *Leishmania* species was different from that observed with *L. major* and *L. amazonensis*. Whether these features are somehow related to IGF-I is an open question that deserves further studies.

7. IGF-I in Human Leishmaniasis

In human leishmaniasis, the infection development is related to the host's genetic and immunological characteristics and the *Leishmania* species' characteristics. We should emphasize the differences presented here on the IGF-I effect on the infection development, depending on the *Leishmania* species. We should also consider the sizable differences between the diseases seen in human patients and murine models.

In murine CL, in the mouse strains susceptible to *L. major* and *L. amazonensis*, the lesions' development is progressive. In these lesions, we find macrophages full of *Leishmania* amastigotes in proliferation [105]. In human active CL caused by these *Leishmania* species, the lesion presents different chronic inflammatory processes and scanty amastigotes [106, 107]. Only in rare diffuse cutaneous leishmaniasis, caused by *L. amazonensis*, the lesions are in some way similar to those observed in the susceptible murine CL model with abundant amastigotes in the lesion [107].

We addressed the VL caused by *L. infantum* and tegumentary leishmaniasis caused by *L. braziliensis* to study the participation of IGF-I in human leishmaniases in Brazil.

7.1. IGF-I in Human Visceral Leishmaniasis. As shown above, the disease progression was initially attributed to *Leishmania* antigen-specific immunosuppression in active VL, but what we notice is an immune activation and imbalance of the immune response. Immunopathogenesis of VL is still not clear, and recently, CD8⁺ T cells were characterized by a gene signature observing the increased expression of specific cytolytic (granzymes A, B, and H and perforin), cytokine signaling (SOCS3, STAT1, JAK2, and JAK3), and immune checkpoint genes (LAG-3, TIM-3, and CTLA-4) [108].

When we evaluated both IGF-I and IGF-binding protein-3 (IGFBP3) serum levels in samples collected from active VL patients, we observed low levels of both IGF-I and IGFBP3 [109]. Based on these unexpected data, mainly in VL, where

we observe massive parasite proliferation in inner organs and considering experimental data showing no evident IGF-I effect on parasite growth, we should consider the participation of IGF-I in another way in the biology of *Leishmania*. Further IGF-I low levels in active VL were also seen in canine VL [109, 110] and human VL patients [111]. We do not have any element to envisage whether an IGF-I low level seen in active VL cases influences nonspecific processes related to parasite growth or adaptive immune response.

Alternatively, considering IGF-I's pleiotropic effect, we regarded it as IGF-I participation in other aspects of disease pathogenesis. High levels of IFN- γ and TNF- α in active VL may explain low IGF-I serum levels [66, 112]. We noticed that IGF-I is linked to hematopoiesis and anemia [113, 114]. Both IGF-I and IGFBP3 serum levels showed a positive correlation with hemoglobin levels in active human VL and canine VL. Thus, we suggested that IGF-I has a pathogenic role in VL anemia without any correlation with cytokine levels. IFN- γ was shown negatively correlated with anemia; thus, we suggested that both IFN- γ and IGF-I contribute to the pathogenesis of anemia in active VL but independently [109]. The experimental data in murine VL showing CD4 $^{+}$ T cells producing IFN- γ with alteration in the stromal micro-environment in bone marrow linked to anemia development reinforced the importance of IFN- γ in the pathogenesis of anemia in active VL [115].

7.2. IGF-I in Human Tegumentary Leishmaniasis. Tegumentary leishmaniasis in Brazil is mostly caused by *L. (Viannia) braziliensis*, which presents as CL, ML, and DL. Studies on pathogenesis show that immune response participates not only in parasite growth control but also in lesion development [116]. In CL, there is a strong T cell response with Th1 cytokine production, such as IFN- γ and IL-12, related to infection control, but if uncontrolled, it may cause tissue damage [117]. The ML has a high specific T cell response, both Th1 and Th2, directed to a Th1-type response. High levels of proinflammatory cytokines, TNF- α and IFN- γ , are produced, which are poorly regulated by IL-10 and TGF- β [118, 119].

Further, comparing infected asymptomatic, CL, and ML cases, a higher level of TNF- α was seen in CL and ML lesions than in asymptomatic individuals. This higher level of TNF- α is involved in lesion development even though it has known anti-*Leishmania* effect [120]. Another study showed that both CD8 $^{+}$ T cells and granzyme were related to lesion development [121]. In a more recent study, transcriptomic analysis in skin samples compared gene expression in cured and noncured CL patients after 90 days of treatment. Gene sets related to cytolytic machinery were significantly more expressed, with higher expression of granzyme (*GZMB gene*), perforin (*PRF1 gene*), and granulysin (*GNLY gene*) [122] in noncured CL patients. Thinking on the participation of IGF-I in the pathogenesis of *L. braziliensis*-caused CL, the role of IGF-I would be more related to inflammatory and healing processes than to parasite growth.

We initially addressed IGF-I in human cases of leishmaniasis, measuring both IGF-I and IGFBP3 serum levels in patients presenting different clinical forms, CL, ML, and DL. In this analysis, both IGF-I and IGFBP3 levels were lower

in ML and DL than CL and healthy controls [89]. Considering the pleiotropic effects of IGF-I and observing a low level of IGF-I in patients with worse clinical presentations such as ML and DL, we may speculate on IGF-I's role in the modulation of the inflammatory process and the maintenance of epidermis and healing process [123–127].

Searching the role of IGF-I by immunohistochemistry in the lesion of 51 human CL caused by *L. braziliensis*, IGF-I was seen related to chronicity and good response to treatment, but not parasite growth, and we relate the findings to the efficient anti-inflammatory response and the known action of IGF-I in wound repair [128].

8. Perspectives on the Use of IGF-I in Therapeutic Interventions in Human Leishmaniasis

IGF-I was associated with other skin diseases where delayed wound healing was related to IGF-I's low production at the injury sites. In conditions like diabetes mellitus, IGF-I has been used in skin ulcer treatment observing the healing with an increase in the IGF-I local level upon hyperbaric oxygen therapy or using IGF-I cream locally [129, 130].

Interference on the IGF-I pathway has been proposed to address treatment strategies in diseases such as cancer, autoimmune diseases, and atherosclerosis [131–133]. One of the suggested targets is the Th17/Treg axis. Th17 cells were associated with protection in VL but were associated with infiltration and disease pathology in human CL and ML [134]. In autoimmune disorders with the participation of Th17 cells, beneficial effects of a systemic recombinant IGF-I treatment were seen through an increase of regulatory T cell levels in affected tissues. Regulation of Th17 cells by IGF-I may occur through modulation of AKT-mTOR and STAT3 signalings [72]. Another target is the Vascular Endothelial Growth Factor A (VEGFA), a key factor in angiogenesis and wound healing process [135].

The possibility to explore the therapeutic use of IGF-I encourages us to proceed with the studies on IGF-I in the pathogenesis of different forms of leishmaniases.

9. Conclusions

In leishmaniases, because the adaptive immune response does not fully explain *Leishmania* infection's outcome, we addressed the participation of IGF-I in infection and disease outcome. Here, we reviewed the role of IGF-I in leishmaniasis experimental models and human patients. IGF-I's effect extends over the biology of *Leishmania*, *Leishmania*-macrophage interaction hitting arginine metabolic pathway in both cells, cytokine modulation, and pathogenic mechanisms of different disease manifestations. The direct effect of IGF-I on *Leishmania* results in its growth in vitro at a specific parasite stage. It influences the disease's course inducing an increase in the skin lesion size and parasite load, especially with *L. major*- and *L. amazonensis*-infected mouse cutaneous leishmaniasis. With other species of *Leishmania*, *L. braziliensis* and *L. infantum*, parasite growth is not evident, bringing

question on the differences in arginine metabolic pathway activation dependent on the parasite species.

IGF-I interacts with cytokines where IFN- γ inhibits, while IL-4 and IL-13 increase its expression in macrophages. In the interaction with IL-4, a cytokine that is a hallmark of susceptibility to *L. major* in murine leishmaniasis, we show IGF-I as an effector element of the IL-4, an unprecedented finding.

Moving to human leishmaniasis, IGF-I was not proven as a factor promoting parasite growth in cutaneous leishmaniasis caused by *L. braziliensis* and visceral leishmaniasis by *L. infantum*. Since patients with more severe diseases such as mucosal, disseminated, and visceral forms presented low IGF-I serum levels, alternative roles were searched. We observed that low IGF-I levels might contribute to the inflammatory response persistence and delayed lesion healing in human cutaneous leishmaniasis and the anemia development in visceral leishmaniasis. We must highlight the complexity of infection revealed depending on the *Leishmania* species and the parasite's developmental stages. Because IGF-I exerts pleiotropic effects on the biology of interaction and disease pathogenesis and can trigger and/or modulate more than 200 genes in certain cells and tissues, IGF-I turns up an interesting tool to explore biological and pathogenic processes underlying infection development. Further, IGF-I pleiotropic effects open the possibility to approach IGF-I as a therapeutical target.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

LCR, EMRS, and HG contributed to the conceptualization, literature search, critical review, data analysis, and manuscript preparation; FNA, AFL, CYO, ORS, and BAU contributed with experimental data and data interpretation, literature search, and manuscript preparation. Luiza C. Reis and Eduardo Milton Ramos-Sánchez contributed equally to this work.

Acknowledgments

We specially acknowledge Magnus Gidlund for the insight to approach IGF-I in leishmaniasis and Claudia M.C. Gomes and Célia M. V. Vendrame for the initial great experimental contributions in the IGF-I leishmaniasis project. This work was supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo (grant 2018/14398-0 and fellowships 2019/25393-1 to LCR, 2017/02959-4 to FNA, and 2014/08340-8 to AFL), Medical Research Council (grant MR/P024661/1), Conselho Nacional de Pesquisa (research fellowship to HG), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (fellowships 1747829 and 88887.572142/2020-00 to BAU and 88882.376675/2019-01 to ORS), Programa Nacional de Becas y Crédito Educativo de Perú (PRONABEC, fellowship to ORS), and LIM 38 (Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo).

References

- [1] S. Burza, S. L. Croft, and M. Boelaert, "Leishmaniasis," *Lancet*, vol. 392, no. 10151, pp. 951–970, 2018.
- [2] K. A. Rogers, G. K. DeKrey, M. L. Mbow, R. D. Gillespie, C. I. Brodskyn, and R. G. Titus, "Type 1 and type 2 responses to *Leishmania major*," *FEMS Microbiology Letters*, vol. 209, no. 1, pp. 1–7, 2002.
- [3] A. Gumy, J. A. Louis, and P. Launois, "The murine model of infection with *Leishmania major* and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds," *International Journal for Parasitology*, vol. 34, no. 4, pp. 433–444, 2004.
- [4] D. Sacks and N. Noben-Trauth, "The immunology of susceptibility and resistance to *Leishmania major* in mice," *Nature Reviews Immunology*, vol. 2, no. 11, pp. 845–858, 2002.
- [5] R. Hurdalay and F. Brombacher, "The role of IL-4 and IL-13 in cutaneous Leishmaniasis," *Immunology Letters*, vol. 161, no. 2, pp. 179–183, 2014.
- [6] D. Liu and J. E. Uzonna, "The early interaction of *Leishmania* with macrophages and dendritic cells and its influence on the host immune response," *Frontiers in Cellular and Infection Microbiology*, vol. 2, p. 83, 2012.
- [7] C. F. Anderson, S. Mendez, and D. L. Sacks, "Nonhealing infection despite Th1 polarization produced by a strain of *Leishmania major* in C57BL/6 mice," *Journal of Immunology*, vol. 174, no. 5, pp. 2934–2941, 2005.
- [8] D. Artis, L. M. Johnson, K. Joyce et al., "Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following *Leishmania major* infection," *Journal of Immunology*, vol. 172, no. 8, pp. 4672–4675, 2004.
- [9] S. Nylen and S. Gautam, "Immunological perspectives of leishmaniasis," *Journal of Global Infectious Diseases*, vol. 2, no. 2, pp. 135–146, 2010.
- [10] P. Launois, K. G. Swihart, G. Milon, and J. A. Louis, "Early production of IL-4 in susceptible mice infected with *Leishmania major* rapidly induces IL-12 unresponsiveness," *Journal of Immunology*, vol. 158, no. 7, pp. 3317–3324, 1997.
- [11] P. Launois, S. Pingel, H. Himmelrich, R. Locksley, and J. Louis, "Different epitopes of the LACK protein are recognized by V beta 4 V alpha 8 CD4+ T cells in H-2b and H-2d mice susceptible to *Leishmania major*," *Microbes and Infection*, vol. 9, no. 11, pp. 1260–1266, 2007.
- [12] B. D. Hontowicz, T. M. Scharton-Kersten, D. E. Jones, and P. Scott, "Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response," *Journal of Immunology*, vol. 159, no. 10, pp. 5024–5031, 1997.
- [13] D. B. Stetson, M. Mohrs, V. Mallet-Designe, L. Teyton, and R. M. Locksley, "Rapid expansion and IL-4 expression by *Leishmania*-specific naive helper T cells in vivo," *Immunity*, vol. 17, no. 2, pp. 191–200, 2002.
- [14] P. Scott, A. Eaton, W. C. Gause, X. di Zhou, and B. Hontowicz, "Early IL-4 production does not predict susceptibility to *Leishmania major*," *Experimental Parasitology*, vol. 84, no. 2, pp. 178–187, 1996.
- [15] A. H. Shankar and R. G. Titus, "T cell and non-T cell compartments can independently determine resistance to *Leishmania major*," *The Journal of Experimental Medicine*, vol. 181, no. 3, pp. 845–855, 1995.

- [16] H. Goto and J. A. Lindoso, "Immunity and immunosuppression in experimental visceral leishmaniasis," *Brazilian Journal of Medical and Biological Research*, vol. 37, no. 4, pp. 615–623, 2004.
- [17] P. M. Kaye, A. J. Curry, and J. M. Blackwell, "Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis," *Journal of Immunology*, vol. 146, no. 8, pp. 2763–2770, 1991.
- [18] C. L. Karp, S. H. el-Safi, T. A. Wynn et al., "In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma," *The Journal of Clinical Investigation*, vol. 91, no. 4, pp. 1644–1648, 1993.
- [19] K. Kemp, "Cytokine-producing T cell subsets in human leishmaniasis," *Archivum Immunologiae et Therapiae Experimentalis (Warsz)*, vol. 48, no. 3, pp. 173–176, 2000.
- [20] E. McFarlane, T. Mokgethi, P. M. Kaye et al., "IL-4 mediated resistance of BALB/c mice to visceral leishmaniasis is independent of IL-4R α signaling via T cells," *Frontiers in Immunology*, vol. 10, p. 1957, 2019.
- [21] H. W. Murray and C. F. Nathan, "Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani," *The Journal of Experimental Medicine*, vol. 189, no. 4, pp. 741–746, 1999.
- [22] D. L. Sacks, S. L. Lal, S. N. Shrivastava, J. Blackwell, and F. A. Neva, "An analysis of T cell responsiveness in Indian kala-azar," *Journal of Immunology*, vol. 138, no. 3, pp. 908–913, 1987.
- [23] R. Kumar, S. B. Chauhan, S. S. Ng, S. Sundar, and C. R. Engwerda, "Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis," *Frontiers in Immunology*, vol. 8, p. 1492, 2017.
- [24] H. Goto and M. Prianti, "Immunoactivation and immunopathogeny during active visceral leishmaniasis," *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 51, no. 5, pp. 241–246, 2009.
- [25] I. M. de Medeiros, A. Castelo, and R. Salomao, "Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis," *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 40, no. 1, pp. 31–34, 1998.
- [26] M. Samant, U. Sahu, S. C. Pandey, and P. Khare, "Role of cytokines in experimental and human visceral Leishmaniasis," *Frontiers in Cellular and Infection Microbiology*, vol. 11, article 624009, 2021.
- [27] S. Gautam, R. Kumar, N. Singh et al., "CD8 T cell exhaustion in human visceral leishmaniasis," *The Journal of Infectious Diseases*, vol. 209, no. 2, pp. 290–299, 2014.
- [28] F. Hamidi, S. Mohammadi-Yeganeh, M. Haji Molla Hoseini et al., "Inhibition of anti-inflammatory cytokines, IL-10 and TGF- β , in Leishmania major infected macrophage by miRNAs: a new therapeutic modality against leishmaniasis," *Microbial Pathogenesis*, vol. 153, article 104777, 2021.
- [29] M. Barral-Netto, A. Barral, C. Brownell et al., "Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism," *Science*, vol. 257, no. 5069, pp. 545–548, 1992.
- [30] A. Barral, M. Barral-Netto, E. C. Yong, C. E. Brownell, D. R. Twardzik, and S. G. Reed, "Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 8, pp. 3442–3446, 1993.
- [31] B. J. Nelson, P. Ralph, S. J. Green, and C. A. Nacy, "Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1," *Journal of Immunology*, vol. 146, no. 6, pp. 1849–1857, 1991.
- [32] K. R. Gantt, S. Schultz-Cherry, N. Rodriguez et al., "Activation of TGF- β by Leishmania chagasi: importance for parasite survival in macrophages," *Journal of Immunology*, vol. 170, no. 5, pp. 2613–2620, 2003.
- [33] V. Rodrigues Jr., "Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis," *Infection and Immunity*, vol. 66, no. 3, pp. 1233–1236, 1998.
- [34] A. Barral, M. Teixeira, P. Reis et al., "Transforming growth factor-beta in human cutaneous leishmaniasis," *The American Journal of Pathology*, vol. 147, no. 4, pp. 947–954, 1995.
- [35] M. Asad, A. Sabur, M. Shadab et al., "EBI-3 chain of IL-35 along with TGF- β synergistically regulate anti-leishmanial immunity," *Frontiers in Immunology*, vol. 10, p. 616, 2019.
- [36] T. di-Blasi, E. L. Telleria, C. Marques et al., "Lutzomyia longipalpis TGF- β has a role in Leishmania infantum chagasi survival in the vector," *Frontiers in Cellular and Infection Microbiology*, vol. 9, p. 71, 2019.
- [37] M. A. Barcinski, D. Schechtman, L. G. Quintao et al., "Granulocyte-macrophage colony-stimulating factor increases the infectivity of Leishmania amazonensis by protecting promastigotes from heat-induced death," *Infection and Immunity*, vol. 60, no. 9, pp. 3523–3527, 1992.
- [38] R. Charlab, C. Blaineau, D. Schechtman, and M. A. Barcinski, "Granulocyte-macrophage colony-stimulating factor is a growth-factor for promastigotes of Leishmania mexicana amazonensis," *The Journal of Protozoology*, vol. 37, no. 5, pp. 352–357, 1990.
- [39] J. Greil, B. Bodendorfer, M. R. Ö. L. And, and W. Solbach, "Application of recombinant granulocyte-macrophage colony-stimulating factor has a detrimental effect in experimental murine leishmaniasis," *European Journal of Immunology*, vol. 18, no. 10, pp. 1527–1534, 1988.
- [40] P. R. L. Machado, F. V. O. Prates, V. Boaventura et al., "A double-blind, randomized trial to evaluate Miltefosine and topical granulocyte macrophage colony-stimulating factor in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil," *Clinical Infectious Diseases*, 2020.
- [41] L. Mendes, J. O. Guerra, B. Costa et al., "Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: a randomized and controlled trial," *International Journal of Infectious Diseases*, vol. 103, pp. 358–363, 2021.
- [42] H. Malta-Santos, K. F. Fukutani, C. A. Sorgi et al., "Multiomic analyses of plasma cytokines, lipidomics, and transcriptomics distinguish treatment outcomes in cutaneous leishmaniasis," *iScience*, vol. 23, no. 12, article 101840, 2020.
- [43] E. Handman and A. W. Burgess, "Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages," *Journal of Immunology*, vol. 122, no. 3, pp. 1134–1137, 1979.
- [44] J. L. Ho, S. G. Reed, E. A. Wick, and M. Giordano, "Granulocyte-macrophage and macrophage colony-stimulating

- factors activate intramacrophage killing of *Leishmania mexicana amazonensis*,” *The Journal of Infectious Diseases*, vol. 162, no. 1, pp. 224–230, 1990.
- [45] W. Y. Weiser, A. van Niel, S. C. Clark, J. R. David, and H. G. Remold, “Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of *Leishmania donovani* by human monocyte-derived macrophages,” *The Journal of Experimental Medicine*, vol. 166, no. 5, pp. 1436–1446, 1987.
- [46] C. L. Scott, L. Roe, J. Curtis et al., “Mice unresponsive to GM-CSF are unexpectedly resistant to cutaneous *Leishmania major* infection,” *Microbes and Infection*, vol. 2, no. 10, pp. 1131–1138, 2000.
- [47] J. I. Jones and D. R. Clemmons, “Insulin-like growth factors and their binding proteins: biological actions,” *Endocrine Reviews*, vol. 16, no. 1, pp. 3–34, 1995.
- [48] L. A. Bach, “IGF-binding proteins,” *Journal of Molecular Endocrinology*, vol. 61, no. 1, pp. T11–T28, 2018.
- [49] A. D. Bakker and R. T. Jaspers, “IL-6 and IGF-1 signaling within and between muscle and bone: how important is the mTOR pathway for bone metabolism?,” *Current Osteoporosis Reports*, vol. 13, no. 3, pp. 131–139, 2015.
- [50] W. S. Cohick and D. R. Clemmons, “The insulin-like growth factors,” *Annual Review of Physiology*, vol. 55, no. 1, pp. 131–153, 1993.
- [51] F. Alvarez-Nava and R. Lanes, “GH/IGF-1 signaling and current knowledge of epigenetics; a review and considerations on possible therapeutic options,” *International Journal of Molecular Sciences*, vol. 18, no. 10, p. 1624, 2017.
- [52] J. Palsgaard, A. E. Brown, M. Jensen, R. Borup, M. Walker, and P. de Meyts, “Insulin-like growth factor I (IGF-I) is a more potent regulator of gene expression than insulin in primary human myoblasts and myotubes,” *Growth Hormone & IGF Research*, vol. 19, no. 2, pp. 168–178, 2009.
- [53] H. D. Luján, M. R. Mowatt, L. J. Helman, and T. E. Nash, “Insulin-like growth factors stimulate growth and L-cysteine uptake by the intestinal parasite *Giardia lamblia*.,” *The Journal of Biological Chemistry*, vol. 269, no. 18, pp. 13069–13072, 1994.
- [54] H. Goto, C. M. C. Gomes, C. E. P. Corbett, H. P. Monteiro, and M. Gidlund, “Insulin-like growth factor I is a growth-promoting factor for *Leishmania* promastigotes and amastigotes,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 22, pp. 13211–13216, 1998.
- [55] C. M. Vendrame, M. D. T. Carvalho, F. J. O. Rios, E. R. Manuli, F. Petitto-Assis, and H. Goto, “Effect of insulin-like growth factor-I on *Leishmania amazonensis* promastigote arginase activation and reciprocal inhibition of NOS2 pathway in macrophage in vitro,” *Scandinavian Journal of Immunology*, vol. 66, no. 2-3, pp. 287–296, 2007.
- [56] C. M. Gomes, H. Goto, C. E. P. Corbett, and M. Gidlund, “Insulin-like growth factor-1 is a growth promoting factor for *Leishmania* promastigotes,” *Acta Tropica*, vol. 64, no. 3-4, pp. 225–228, 1997.
- [57] H. You, G. N. Gobert, M. G. Duke et al., “The insulin receptor is a transmission blocking veterinary vaccine target for zoonotic *Schistosoma japonicum*,” *International Journal for Parasitology*, vol. 42, no. 9, pp. 801–807, 2012.
- [58] L. S. Rodrigues, E. da Silva Maeda, M. E. C. Moreira et al., “*Mycobacterium leprae* induces insulin-like growth factor and promotes survival of Schwann cells upon serum withdrawal,” *Cellular Microbiology*, vol. 12, no. 1, pp. 42–54, 2010.
- [59] L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino, “Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans,” *American Journal of Physiology. Endocrinology and Metabolism*, vol. 295, no. 5, pp. E991–E999, 2008.
- [60] M. F. White, “The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action,” *Recent Progress in Hormone Research*, vol. 53, pp. 119–138, 1998.
- [61] L. Soon, L. Flechner, J. S. Gutkind et al., “Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression,” *Molecular and Cellular Biology*, vol. 19, no. 5, pp. 3816–3828, 1999.
- [62] J. Frystyk, “Free insulin-like growth factors – measurements and relationships to growth hormone secretion and glucose homeostasis,” *Growth Hormone & IGF Research*, vol. 14, no. 5, pp. 337–375, 2004.
- [63] T. Hehlgans and K. Pfeffer, “The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games,” *Immunology*, vol. 115, no. 1, pp. 1–20, 2005.
- [64] A. M. Valverde, M. Benito, and M. Lorenzo, “The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance,” *Acta Physiologica Scandinavica*, vol. 183, no. 1, pp. 59–73, 2005.
- [65] L. C. Reis, E. M. Ramos-Sánchez, F. Petitto-Assis et al., “Insulin-like growth factor-I as an effector element of the cytokine IL-4 in the development of a *Leishmania major* infection,” *Mediators of Inflammation*, vol. 2018, Article ID 9787128, 17 pages, 2018.
- [66] S. Arkins, N. Rebeiz, D. L. Brunke-Reese, A. Biragyn, and K. W. Kelley, “Interferon-gamma inhibits macrophage insulin-like growth factor-I synthesis at the transcriptional level,” *Molecular Endocrinology*, vol. 9, no. 3, pp. 350–360, 1995.
- [67] M. W. Wynes and D. W. Riches, “Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13,” *Journal of Immunology*, vol. 171, no. 7, pp. 3550–3559, 2003.
- [68] R. Kooijman and A. Coppens, “Insulin-like growth factor-I stimulates IL-10 production in human T cells,” *Journal of Leukocyte Biology*, vol. 76, no. 4, pp. 862–867, 2004.
- [69] E. W. Johnson, L. A. Jones, and R. W. Kozak, “Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes,” *Journal of Immunology*, vol. 148, no. 1, pp. 63–71, 1992.
- [70] M. E. Segrelin, A. Galeano, A. Roldán, and R. Schillaci, “Insulin-like growth factor-1 receptor regulation in activated human T lymphocytes,” *Hormone Research*, vol. 59, no. 6, pp. 276–280, 2003.
- [71] P. T. Walsh and R. O’Connor, “The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis,” *European Journal of Immunology*, vol. 30, no. 4, pp. 1010–1018, 2000.
- [72] D. DiToro, S. N. Harbour, J. K. Bando et al., “Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity,” *Immunity*, vol. 52, no. 4, pp. 650–667.e10, 2020.
- [73] C. M. Gomes, H. P. Monteiro, M. Gidlund, C. E. P. Corbett, and H. Goto, “Insulin-like growth factor-I induces

- phosphorylation in Leishmania (Leishmania) mexicana promastigotes and amastigotes,” *The Journal of Eukaryotic Microbiology*, vol. 45, no. 3, pp. 352–355, 1998.
- [74] C. M. Gomes, H. Goto, A. C. Magnanelli et al., “Characterization of the receptor for insulin-like growth factor on Leishmania promastigotes,” *Experimental Parasitology*, vol. 99, no. 4, pp. 190–197, 2001.
- [75] K. Drakenberg, V. R. Sara, S. Falkmer, S. Gammeltoft, C. Maake, and M. Reinecke, “Identification of IGF-1 receptors in primitive vertebrates,” *Regulatory Peptides*, vol. 43, no. 1-2, pp. 73–81, 1993.
- [76] I. Navarro, B. Leibush, T. W. Moon et al., “Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors,” *Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology*, vol. 122, no. 2, pp. 137–153, 1999.
- [77] C. M. Gomes, H. Goto, V. L. Ribeiro da Matta, M. D. Laurienti, M. Gidlund, and C. E. Corbett, “Insulin-like growth factor (IGF)-I affects parasite growth and host cell migration in experimental cutaneous leishmaniasis,” *International Journal of Experimental Pathology*, vol. 81, no. 4, pp. 249–255, 2000.
- [78] N. Wanases, C. L. MacLeod, L. G. Ellies, and L. Soong, “L-arginine and cationic amino acid transporter 2B regulate growth and survival of Leishmania amazonensis amastigotes in macrophages,” *Infection and Immunity*, vol. 75, no. 6, pp. 2802–2810, 2007.
- [79] F. Y. Liew, S. Millott, C. Parkinson, R. M. Palmer, and S. Moncada, “Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine,” *Journal of Immunology*, vol. 144, no. 12, pp. 4794–4797, 1990.
- [80] S. C. Roberts, M. J. Tancer, M. R. Polinsky, K. M. Gibson, O. Heby, and B. Ullman, “Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania,” *The Journal of Biological Chemistry*, vol. 279, no. 22, pp. 23668–23678, 2004.
- [81] M. F. da Silva and L. M. Floeter-Winter, “Arginase in Leishmania,” *Sub-Cellular Biochemistry*, vol. 74, pp. 103–117, 2014.
- [82] L. C. Reis, E. M. Ramos-Sanchez, and H. Goto, “The interactions and essential effects of intrinsic insulin-like growth factor-I on Leishmania (Leishmania) major growth within macrophages,” *Parasite Immunology*, vol. 35, no. 7-8, pp. 239–244, 2013.
- [83] Y. Jiang, S. C. Roberts, A. Jardim et al., “Ornithine decarboxylase gene deletion mutants of Leishmania donovani,” *The Journal of Biological Chemistry*, vol. 274, no. 6, pp. 3781–3788, 1999.
- [84] J. M. Boitz, C. A. Gilroy, T. D. Olenyik et al., “Arginase is essential for survival of Leishmania donovani promastigotes but not intracellular amastigotes,” *Infection and Immunity*, vol. 85, no. 1, 2017.
- [85] C. C. Stempin, L. R. Dulgerian, V. V. Garrido, and F. M. Cerban, “Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals,” *Journal of Biomedicine & Biotechnology*, vol. 2010, Article ID 683485, 10 pages, 2010.
- [86] T. Ferreira-Paes, K. S. Charret, M. R. S. Ribeiro, R. F. Rodrigues, and L. L. Leon, “Comparative analysis of biological aspects of Leishmania infantum strains,” *PLoS One*, vol. 15, no. 12, article e0230545, 2020.
- [87] F. Marques, S. Vale-Costa, T. Cruz et al., “Studies in the mouse model identify strain variability as a major determinants of disease outcome in Leishmania infantum infection,” *Parasites & Vectors*, vol. 8, no. 1, p. 644, 2015.
- [88] C. M. Vendrame, L. D. Souza, M. D. T. Carvalho, K. Salgado, E. M. Carvalho, and H. Goto, “Insulin-like growth factor-I induced and constitutive arginase activity differs among isolates of Leishmania derived from patients with diverse clinical forms of Leishmania braziliensis infection,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 104, no. 568, pp. 566–568, 2010.
- [89] L. D. de Souza, C. M. V. Vendrame, A. R. de Jesus et al., “Insulin-like growth factor-I serum levels and their biological effects on Leishmania isolates from different clinical forms of American tegumentary leishmaniasis,” *Parasites & Vectors*, vol. 9, no. 1, p. 335, 2016.
- [90] M. R. Barrios, V. C. Campos, N. T. A. Peres et al., “Macrophages from subjects with isolated GH/IGF-I deficiency due to a GHRH receptor gene mutation are less prone to infection by Leishmania amazonensis,” *Frontiers in Cellular and Infection Microbiology*, vol. 9, p. 311, 2019.
- [91] C. M. Vendrame, M. D. T. Carvalho, A. G. Tempone, and H. Goto, “Insulin-like growth factor-I induces arginase activity in Leishmania amazonensis amastigote-infected macrophages through a cytokine-independent mechanism,” *Mediators of Inflammation*, vol. 2014, Article ID 475919, 13 pages, 2014.
- [92] R. Kooijman, E. L. Hooghe-Peters, and R. Hooghe, “Prolactin, growth hormone, and insulin-like growth factor-I in the immune system,” *Advances in Immunology*, vol. 63, pp. 377–454, 1996.
- [93] K. W. Kelley, D. A. Weigent, and R. Kooijman, “Protein hormones and immunity,” *Brain, Behavior, and Immunity*, vol. 21, no. 4, pp. 384–392, 2007.
- [94] J. C. O’Connor, R. H. McCusker, K. Strle, R. W. Johnson, R. Dantzer, and K. W. Kelley, “Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology,” *Cellular Immunology*, vol. 252, no. 1-2, pp. 91–110, 2008.
- [95] E. Witkowska-Sedek and B. Pyrzak, “Chronic inflammation and the growth hormone/insulin-like growth factor-1 axis,” *Central European Journal of Immunology*, vol. 45, no. 4, pp. 469–475, 2020.
- [96] Francesca Cirillo, Pietro Lazzeroni, C. Sartori, and M. E. Street, “Inflammatory diseases and growth: effects on the GH-IGF axis and on growth plate,” *International Journal of Molecular Sciences*, vol. 18, no. 9, p. 1878, 2017.
- [97] D. Choukair, U. Hügel, A. Sander, L. Uhlmann, and B. Tönshoff, “Inhibition of IGF-I-related intracellular signaling pathways by proinflammatory cytokines in growth plate chondrocytes,” *Pediatric Research*, vol. 76, no. 3, pp. 245–251, 2014.
- [98] X. Yu, C. Xing, Y. Pan, H. Ma, J. Zhang, and W. Li, “IGF-1 alleviates ox-LDL-induced inflammation via reducing HMGB1 release in HAECS,” *Acta Biochimica et Biophysica Sinica Shanghai*, vol. 44, no. 9, pp. 746–751, 2012.
- [99] H. Zatorski, M. Marynowski, and J. Fichna, “Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy,” *Pharmacological Reports*, vol. 68, no. 4, pp. 809–815, 2016.
- [100] J. Guo, D. Zheng, W. F. Li, H. R. Li, A. D. Zhang, and Z. C. Li, “Insulin-like growth factor 1 treatment of MSCs attenuates inflammation and cardiac dysfunction following MI,” *Inflammation*, vol. 37, no. 6, pp. 2156–2163, 2014.

- [101] J. B. C. Carvalheira, H. G. Zecchin, and M. J. A. Saad, “Vias de Sinalização da Insulina,” *Arquivos Brasileiros de Endocrinologia e Metabologia*, vol. 46, no. 4, pp. 419–425, 2002.
- [102] J. P. Barrett, A. M. Minogue, A. Falvey, and M. A. Lynch, “Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages,” *Experimental Cell Research*, vol. 335, no. 2, pp. 258–268, 2015.
- [103] H. Qi, J. Ji, N. Wanasen, and L. Soong, “Enhanced replication of *Leishmania amazonensis* amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis,” *Infection and Immunity*, vol. 72, no. 2, pp. 988–995, 2004.
- [104] T. R. de Moura, F. O. Novais, F. Oliveira et al., “Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by *Leishmania braziliensis*,” *Infection and Immunity*, vol. 73, no. 9, pp. 5827–5834, 2005.
- [105] C. Loeillet, A. L. Banuls, and M. Hide, “Study of *Leishmania* pathogenesis in mice: experimental considerations,” *Parasites & Vectors*, vol. 9, no. 1, p. 144, 2016.
- [106] O. E. Akilov, A. Khachemoune, and T. Hasan, “Clinical manifestations and classification of old world cutaneous leishmaniasis,” *International Journal of Dermatology*, vol. 46, no. 2, pp. 132–142, 2007.
- [107] F. T. Silveira, R. Lainson, C. M. de Castro Gomes, M. D. Laurenti, and C. E. P. Corbett, “Immunopathogenic competences of *Leishmania* (V.) *braziliensis* and *L.* (L.) *amazonensis* in American cutaneous leishmaniasis,” *Parasite Immunology*, vol. 31, no. 8, pp. 423–431, 2009.
- [108] B. Singh, S. Bhushan Chauhan, R. Kumar et al., “A molecular signature for CD8⁺ T cells from visceral leishmaniasis patients,” *Parasite Immunology*, vol. 41, no. 11, article e12669, 2019.
- [109] F. A. Pinho, C. M. V. Vendrame, B. L. L. Maciel et al., “Association between insulin-like growth factor-I levels and the disease progression and anemia in visceral leishmaniasis,” *The American Journal of Tropical Medicine and Hygiene*, vol. 100, no. 4, pp. 808–815, 2019.
- [110] F. A. Pinho, N. A. Magalhães, K. R. Silva et al., “Divergence between hepatic insulin-like growth factor (IGF)-I mRNA expression and IGF-I serum levels in *Leishmania* (*Leishmania*) infantum chagasi-infected dogs,” *Veterinary Immunology and Immunopathology*, vol. 151, no. 1-2, pp. 163–167, 2013.
- [111] C. M. Gomes, D. Giannella-Neto, M. E. A. Gama, J. C. R. Pereira, M. B. Campos, and C. E. P. Corbett, “Correlation between the components of the insulin-like growth factor I system, nutritional status and visceral leishmaniasis,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 101, no. 7, pp. 660–667, 2007.
- [112] J. Fan, D. Char, G. J. Bagby, M. C. Gelato, and C. H. Lang, “Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor,” *The American Journal of Physiology*, vol. 269, 5 Part 2, pp. R1204–R1212, 1995.
- [113] W. Zumkeller, “The insulin-like growth factor system in hematopoietic cells,” *Leukemia & Lymphoma*, vol. 43, no. 3, pp. 487–491, 2002.
- [114] M. A. Marini, G. C. Mannino, T. V. Fiorentino, F. Andreozzi, F. Perticone, and G. Sesti, “A polymorphism at IGF1 locus is associated with anemia,” *Oncotarget*, vol. 8, no. 20, pp. 32398–32406, 2017.
- [115] O. Preham, F. A. Pinho, A. I. Pinto et al., “CD4(+) T cells alter the stromal microenvironment and repress medullary erythropoiesis in murine visceral Leishmaniasis,” *Frontiers in Immunology*, vol. 9, p. 2958, 2018.
- [116] K. J. Gollob, A. G. Viana, and W. O. Dutra, “Immunoregulation in human American leishmaniasis: balancing pathology and protection,” *Parasite Immunology*, vol. 36, no. 8, pp. 367–376, 2014.
- [117] M. G. Vieira, F. Oliveira, S. Arruda et al., “B-cell infiltration and frequency of cytokine producing cells differ between localized and disseminated human cutaneous leishmaniasis,” *Memórias do Instituto Oswaldo Cruz*, vol. 97, no. 7, pp. 979–983, 2002.
- [118] V. S. Amato, H. F. de Andrade, and M. I. Duarte, “Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment,” *Acta Tropica*, vol. 85, no. 1, pp. 39–49, 2003.
- [119] O. Bacellar, H. Lessa, A. Schriefer et al., “Up-regulation of Th1-type responses in mucosal leishmaniasis patients,” *Infection and Immunity*, vol. 70, no. 12, pp. 6734–6740, 2002.
- [120] A. Giudice, C. Vendrame, C. Bezerra et al., “Macrophages participate in host protection and the disease pathology associated with *Leishmania braziliensis* infection,” *BMC Infectious Diseases*, vol. 12, no. 1, p. 75, 2012.
- [121] T. M. Cardoso, Á. Machado, D. L. Costa et al., “Protective and pathological functions of CD8+ T cells in *Leishmania braziliensis* infection,” *Infection and Immunity*, vol. 83, no. 3, pp. 898–906, 2015.
- [122] C. F. Amorim, F. O. Novais, B. T. Nguyen et al., “Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis,” *Science Translational Medicine*, vol. 11, no. 519, article eaax4204, 2019.
- [123] G. Kratz, M. Lake, and M. Gidlund, “Insulin like growth factor-1 and -2 and their role in the re-epithelialisation of wounds; interactions with insulin like growth factor binding protein type 1,” *Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery*, vol. 28, no. 2, pp. 107–112, 1994.
- [124] A. Tavakkol, J. Varani, J. T. Elder, and C. C. Zouboulis, “Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor,” *Archives of Dermatological Research*, vol. 291, no. 12, pp. 643–651, 1999.
- [125] L. L. Sharp, J. M. Jameson, G. Cauvi, and W. L. Havran, “Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1,” *Nature Immunology*, vol. 6, no. 1, pp. 73–79, 2005.
- [126] P. N. Rocha, R. P. Almeida, O. Bacellar et al., “Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis,” *The Journal of Infectious Diseases*, vol. 180, no. 5, pp. 1731–1734, 1999.
- [127] A. Ribeiro-de-Jesus, R. P. Almeida, H. Lessa, O. Bacellar, and E. M. Carvalho, “Cytokine profile and pathology in human leishmaniasis,” *Brazilian Journal of Medical and Biological Research*, vol. 31, no. 1, pp. 143–148, 1998.
- [128] C. de O Mendes-Aguiar, C. Lopes-Siqueira, F. Pettito-Assis et al., “Dual role of insulin-like growth factor (IGF)-I in American tegumentary leishmaniasis,” *Journal of Immunology Research*, vol. 2021, Article ID 6657785, 7 pages, 2021.
- [129] F. Aydin, A. Kaya, L. Karapinar et al., “IGF-1 increases with hyperbaric oxygen therapy and promotes wound healing in

- diabetic foot ulcers,” *Journal Diabetes Research*, vol. 2013, article 567834, 6 pages, 2013.
- [130] R. A. Achar, T. C. Silva, E. Achar, R. B. Martines, and J. L. M. Machado, “Use of insulin-like growth factor in the healing of open wounds in diabetic and non-diabetic rats,” *Acta Cirúrgica Brasileira*, vol. 29, no. 2, pp. 125–131, 2014.
- [131] D. Leroith, H. Werner, D. Beitner-Johnson, and A. T. Roberts JR., “Molecular and cellular aspects of the insulin-like growth factor I receptor,” *Endocrine Reviews*, vol. 16, no. 2, pp. 143–163, 1995.
- [132] D. Sachdev and D. Yee, “Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 11, no. 1, pp. 27–39, 2006.
- [133] D. R. Clemmons, “Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer,” *Nature Reviews. Drug Discovery*, vol. 6, no. 10, pp. 821–833, 2007.
- [134] G. K. Katara, A. Raj, R. Kumar et al., “Analysis of localized immune responses reveals presence of Th17 and Treg cells in cutaneous leishmaniasis due to Leishmania tropica,” *BMC Immunology*, vol. 14, no. 1, p. 52, 2013.
- [135] M. Huang, X. Huang, B. Jiang et al., “linc00174-EZH2-ZNF24/Runx1-VEGFA regulatory mechanism modulates post-burn wound healing,” *Molecular Therapy-Nucleic Acids*, vol. 21, pp. 824–836, 2020.
- [136] F. A. Costa, H. Goto, L. C. B. Saldanha et al., “Histopathologic patterns of nephropathy in naturally acquired canine visceral leishmaniasis,” *Veterinary Pathology*, vol. 40, no. 6, pp. 677–684, 2003.